Legal & General Group’s Zevra Therapeutics ZVRA Stock Holding History

Legal & General Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.2M	Buy	1,201,668 +38,578	+3%	+$429K	﹤0.01%	939
2026 Q1	$10.8M	Buy	1,163,090 +65,102	+6%	+$587K	﹤0.01%	1078
2025 Q4	$9.84M	Buy	1,097,988 +44,589	+4%	+$422K	﹤0.01%	1180
2025 Q3	$10M	Buy	1,053,399 +117,722	+13%	+$1.18M	﹤0.01%	1215
2025 Q2	$8.24M	Buy	935,677 +197,940	+27%	+$1.61M	﹤0.01%	1289
2025 Q1	$5.52M	Buy	737,737 +732,436	+13,817%	+$5.82M	﹤0.01%	1480
2024 Q4	$44.2K	Buy	5,301 +762	+17%	+$6.5K	﹤0.01%	2803
2024 Q3	$31.5K	Buy	4,539 +688	+18%	+$4.67K	﹤0.01%	2881
2024 Q2	$18.9K	Buy	3,851 +526	+16%	+$2.49K	﹤0.01%	3043
2024 Q1	$19.3K	Hold	3,325	–	–	﹤0.01%	2981
2023 Q4	$21.8K	Hold	3,325	–	–	﹤0.01%	2998
2023 Q3	$16K	Hold	3,325	–	–	﹤0.01%	3114
2023 Q2	$17K	Buy	+3,325	New	+$17.9K	﹤0.01%	3181
2022 Q2	–	Sell	-2,642	Closed	-$13K	–	3677
2022 Q1	$13K	Hold	2,642	–	–	﹤0.01%	3345
2021 Q4	$23K	Hold	2,642	–	–	﹤0.01%	3236
2021 Q3	$25K	Hold	2,642	–	–	﹤0.01%	3199
2021 Q2	$34K	Buy	+2,642	New	+$28.4K	﹤0.01%	3093

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group's ZVRA Position: Q2 2026 in Review

Legal & General Group increased its Zevra Therapeutics (ZVRA) stake by 3.3% in Q2 2026, buying an estimated $429K and bringing the position to 1,201,668 shares worth $17.2M. The position accounts for ﹤0.01% of the portfolio, ranked #939.

Legal & General Group first reported a position in ZVRA in Q2 2021 and has held it in 17 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Legal & General Group held 1,201,668 shares of Zevra Therapeutics worth $17.2M as of Q2 2026.
Legal & General Group bought 38,578 Zevra Therapeutics shares in Q2 2026, an estimated $429K.
Zevra Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #939 holding.
Legal & General Group first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 17 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.